A clinical-stage company focusing on botanical drugs and high-value herbal ingredients of Malaysian and Southeast Asian origin.
Medika Natura, which was established in 2006, is the developer and marketer of Labeesity®, a dietary supplement that tackles obesity and metabolic syndrome. SKF7™, the active ingredient in Labeesity®, is derived from Labisia pumila, also known as Kacip Fatimah.
In 2015, the company was appointed as an Anchor Company by Malaysia’s Ministry of Agriculture and Food Industry (MAFI) under its National Key Economic Area (NKEA), Entry Point Project 1, High Value Herbal Products Program, to conduct pre-clinical and clinical research on Labisia pumila as an anti-obesity botanical drug. This was a continuation of the R&D work led by Prof Zhari Ismail from Universiti Sains Malaysia (USM) and the impetus for the company to commercialize Labisia pumila as an anti-obesity botanical drug. Subsequently, Labeesity® was born.
Labeesity® contains SKF7™, a proprietary, standardized, botanical bio-active compound which meets the industry’s highest quality and safety standards. After extensive pre-clinical trials, Labeesity® was approved by the National Pharmaceutical Regulatory Agency (NPRA) in Malaysia as a Traditional Medicine in 2017. Laabesity® has also received approvals from Badan Pengawas Obat dan Makanan, Indonesia, and the Health Sciences Authority, Singapore.
Stringent Quality and Safety Standards.
In 2020, SKF7™ became the first ever Malaysian-made botanical extract to receive clearance from the United States Food and Drug Administration (USFDA) as a New Dietary Ingredient (NDIN). Medika Natura was the first ever Malaysian company to receive USFDA clearance. We are expecting to receive Novel Food clearance for SKF7™ from the European Food Safety Authority (EFSA) soon.
With these, Medika Natura will be the first Malaysian company to market botanical ingredients of Malaysian origin carrying USFDA and EU approvals.
Each one of Medika Natura’s products is put through a stringent end-to-end quality control mechanism using our proprietary technology platform, PhytoProfile™, to ensure they maintain consistent safety, quality and efficacy standards.
Our products are currently undergoing Randomised Human Clinical Trials in Malaysia and Indonesia. This same study has just been completed in India. We have also completed multiple pre-clinical studies related to the treatment of obesity, diabetes, cancer and Covid-19, in collaboration with leading public universities and research institutions.
With a basis in science, technology and innovation, Medika Natura is scaling up in Asia and moving into the US and EU with diversified ingredients and product pipelines. We are poised to emerge as a global company that continues to develop innovative products which make things that matter, better.